A Congressional committee is stepping up pressure on three of the largest purveyors of opioids — Purdue Pharma, Mallinckrodt (MNK), and Insys Therapeutics (INSY) — by seeking a raft of documents concerning their controversial marketing and distribution practices.
In letters sent on Thursday to the companies, the House Energy and Commerce Committee asked the drug makers to provide information pertinent to their role in the opioid crisis, such as relationships with doctors, oversight of suspicious orders, funding to outside organizations, training for sales reps, and policies for educational programs, among other things.
The missives, which were signed by both Republican and Democratic committee leaders, are part of an ongoing investigation the committee has been conducting into opioid manufacturers and wholesalers. And the latest requests for information draw on disclosures contained in a growing mix of news reports, court documents, and related government probes into these companies and others.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
